Condition: Juvenile Idiopathic Arthritis · Sponsor: AbbVie
Juvenile Idiopathic Arthritis (JIA) is the most common type of arthritis that affects children. The term "idiopathic" means "of unknown origin". It is a chronic (long-lasting) disease that causes swelling, warmth, and pain of one or more small joints. Systemic JIA ia a rare and serious form of JIA. Systemic" means it may affect not only the joints but other parts of the body, including the liver, lungs and heart. sJIA is more severe and can be more challenging to diagnose and treat than other types of juvenile idiopathic arthritis. It is a lifelong disease for many patients and can continue into adulthood. This study will assess how safe and effective upadacitinib is in treating pediatric and adolescent participants aged 1 to \< 18 with systemic juvenile idiopathic arthritis (sJIA) and will include a tocilizumab treatment arm for reference. Adverse events and change in the disease activity will be assessed. Upadacitinib is an investigational drug being developed for the treatment of sJIA. Participants are assigned to 1 of 2 cohorts. In cohort 1, participants will receive upadacitinib or tocilizumab reference. In cohort 2, participants will receive upadacitinib. Approximately 90 participants with sJIA will be enrolled in approximately 45 sites worldwide. Participants will receive upadacitinib oral tablets once daily or oral solution twice daily or tocilizumab subcutaneous injection or intravenous infusion as per local label for 52 weeks and followed for approximately 30 days…
This description comes directly from the study's public registry record.
ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
Always discuss trial participation with your own doctor first.
| Phoenix Children's Hospital /ID# 253403 | Phoenix, Arizona, United States | Recruiting |
| Childrens National Medical Center /ID# 253344 | Washington D.C., District of Columbia, United States | Recruiting |
| New York Medical College /ID# 253437 | Valhalla, New York, United States | Recruiting |
| Levine Children's Hospital /ID# 253491 | Charlotte, North Carolina, United States | Completed |
| Cincinnati Childrens Hospital Medical Center /ID# 251827 | Cincinnati, Ohio, United States | Recruiting |
| Randall Children's Hospital /ID# 251829 | Portland, Oregon, United States | Recruiting |
| Instituto CAICI S.R.L /ID# 251448 | Rosario, Santa Fe Province, Argentina | Recruiting |
| Centro de Investigaciones Medicas Tucuman /ID# 251781 | San Miguel de Tucumán, Tucumán Province, Argentina | Recruiting |
| Hospital de Niños de la Santisima Trinidad /ID# 252736 | Córdoba, Argentina | Recruiting |
| Monash Health - Monash Medical Centre - Clayton /ID# 251691 | Clayton, Victoria, Australia | Completed |
| Royal Children's Hospital /ID# 251663 | Parkville, Victoria, Australia | Completed |
| Landeskrankenhaus Bregenz /ID# 266317 | Bregenz, Vorarlberg, Austria | Recruiting |
+ 35 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05609630